To compare plasma endothelin (ET)-1 level and ET-1 mRNA level in peripheral blood monocytes of patients undergoing hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD).
Design
Endothelin-1 mRNA level in peripheral blood monocytes and plasma ET -1 level were studied in 30 HD patients, 15 CAPD patients, 20 chronic renal failure patients not being dialyzed, and 20 normal healthy controls. Hemodialysis patients were dialyzed three times per week with a bicarbonate dialysate. Different types of dialyzer membrane, viz., cellulose triacetate, cuprophane, poly-sulfone, polyacrylonitrile, and ethylenevinylalcohol were used in 8,6,6,5, and 5 patients, respectively. Continuous ambulatory peritoneal dialysis patients were dialyzed with four daily exchanges of a 2-L dialysate containing glucose at a concentration of 1.5% to 2.5%.
Results
Higher levels of ET -1 mRNA in monocytes were observed in HD patients than in CAPD patients (p < 0.01), chronic renal failure patients (p < 0.01), or normal healthy controls (p < 0.001). The level of ET -1 mRNA in monocytes at the end of HD was not significantly higher than that at the start of HD. ln addition, these mRNA levels in HD patients showed littledifference with different types of dialysis membrane. Plasma ET -1 level in HD patients (10.2 ± 2.4 pg/mL) was also higher than that in CAPD patients (7.8 ± 1.6 pg/mL, p < 0.01), in chronic renal failure patients (4.8 ± 1.2 pg/mL, p < 0.01), or in normal controls (2.6 ± 0.8 pg/mL, p < 0.001).
Conclusion
Dialysis itself did not significantly affect ET -1 mRNA levels in monocytes. Chronic stimulation of peripheral blood monocytes may be associated with higher levels of ET -1 mRNA and plasma ET -1 in HD patients than in CAPD patients.
VlassopoulosD., DerayG., CarayonA., MaistreG., JacobsC.Blood and peritoneal levels of endothelin in continuous ambulatory peritoneal dialysis patients.Nephron1995; 69: 273–6.
4.
MooreK., WendenJ., FrazerM., KaraniJ., WilliamsR., BadrK.Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.N Engl J Med1992; 327: 1774–8.
5.
SorensenS.S., MadsenJ.K., PedersenE.B.Systemic and renal effect of intravenous infusion of endothelin-l in healthy human volunteers.Am J Physiol1994; 266: F411–18.
6.
BrownM., ChouS.Y., PorushJ.G.Endothelins and kidney diseases.Nephron1996; 72: 375–82.
7.
RostandS.G., KirkK.A., RutskyE.A.Relationship of coronary risk factor to hemodialysis-associated ischemic heart disease.Kidney Int1982; 22: 304–8.
8.
AndoM., LundkvistI., BergströmJ., LindholmB.Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients.Kidney Int1996; 49: 773–80.
9.
BobikA., GroomsA., MillarJ.A., MitchellA., GrinpukelS.Growth factor activity of endothelin on vascular smooth muscle.Am J Physiol1990; 258: C408–15.
10.
KahalehM.B.Endothelin, an endothelial-dependent vasoconstriction in scleroderma: enhanced production and profibrotic action.Arthritis Rheum1991; 34: 978–83.
11.
LermanA., EdwardsB.S., HalletJ.W., HeubleinD.M., SandbergS.M., BurnettJ.C.JrCirculating and tissue endothelin immunoreactivity in advanced atherosclerosis.N Engl J Med1991; 325: 997–1001.
12.
EhrenreichH., AndersonR.W., FoxC.H., RieckmannP., HoffmanG.S., TravisW.D.Endothelin peptides with potent vasoactive properties are produced by human macrophages.J Exp Med1990; 172: 1741–8.
13.
GasconA., OrfaoA., LermaJ.L., CiudadJ., LopezA., HernandezM.D.Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients.Am J Kidney Dis1996; 27: 373–9.
14.
HarveyK.B., BlumenkranzM.J., LevineS.E., BlackburnG.L.Nutritional assessment and treatment in chronic renal failure.Am J Clin Nutr1980; 33: 1586–97.
15.
NakamuraT., EbiharalShiratol, FukuiM., TominoY., KoideH.Endothelin-l mRNA expression by peripheral blood monocytes in IgAnephropathy.Lancet1993; 342: 1147–8.
16.
EbiharaI., NakamuraT., SuzukiS., TominoY., KoideH.Proto-oncogene expression in peripheral blood mononuclear cells in IgA nephropathy.Kidney Int1991; 39: 946–50.
InoueA., YanagisawaM., KimuraY., KasuyaY., MiyauchiT., GotoK.The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.Proc Natl Acad Sci USA1989; 86: 2863–7.
19.
InoueA., YanagisawaM., TakuwaY., MitsuiY., KobayashiM., MasakiT.The human preproendothelin-l gene. Complete nucleotide sequence and regulation of expression.J Biol Chem1989; 264: 14954–9.
20.
AdachiM., YangY.Y., FuruichiY., MiyamotoC.Cloning and characterization of cDNA encoding human A-type endothelin receptor.Biochem Biophys Res Commun1991; 180: 1265–72.
21.
SakuraiT., YanagisawaM., TakuwaY., MiyazakiH., KimuraS., GotoK.Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor.Nature1990; 348: 732–5.
22.
NakamuraT., EbiharaI., FukuiM., OsadaS., TominoY., MasakiT.Modulation of endothelin and endothelin receptor gene expression in glomeruli of aminonucleoside nephrosis.J Am Soc Nephrol1995; 5: 1585–90.
23.
YamaguchiT., IwanoM., KuboA., HirayamaT., AkaiY., HoriiY.IL-6 mRNA synthesis by peripheral blood mononuclear cells (PBMC) in patients with chronic renal failure.Clin Exp Immunol1996; 103: 279–84.
24.
GerrityR.G.The role of monocytes in atherogenesis II. Migration of foam cells from atherosclerotic lesions.Am J Pathol1981; 103: 181–200.
25.
WinklesJ.A., AlbertsG.F., BrogiE., LibbyP.Endothelin-l and endothelin receptor mRNA expression in normal and atherosclerotic human arteries.Biochem Biophys Res Commun1993; 191: 1081–8.
26.
NakamuraT., FukuiM., EbiharaI., OsadaS., TakahashiT., TominoY.Effects of a low-protein diet on glomerular endothelin family gene expression in experimental focal glomerular sclerosis.Clin Sci1995; 88: 29–37
27.
SchraderJ., NeuhausK.L., TebbeU., KosteringH., SchelerF.Fibrinolytic activity in renal venous blood in man.Klin Wochenschr1986; 64: 587–9.
28.
RennickR.E., MilnerP., BurnstockG.Thrombin stimulates release of endothelin and vasopressin, but not substance P, from isolated rabbit tracheal epithelial cells.Eur J Pharmacol1993; 230: 367–70.
29.
EmoriT., HirataY., ImaiT., OhtaK., KannoK., EguchiS.Cellular mechanism of thrombin on endothelin-l biosynthesis and release in bovine endothelial cells.Biochem Pharmacol1992; 44: 2409–11.
30.
SchulzE., RuschitzkaF., LuedersS., HeydenbluthR., SchraderJ., MullerG.A.Effects of endothelin on hemodynamics, prostaglandins, blood coagulation and renal function.Kidney Int1995; 47: 795–801.
31.
KawagishiT., NishizawaY., KonishiT., KawasakiK., EmotoM., ShojiT.High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia.Kidney Int1995; 48: 820–6.
32.
KohanD.E.Production of endothelin-l by rat mesangial cells: regulation by tumor necrosis factor.J Lab Clin Med1992; 119: 477–84.
33.
XinX., CaiY., MatsumotoK., AguiT.Endothelin induced interleukin-6 production by rat aortic endothelial cells.Endocrinology1995; 136: 132–7.
HerbelinA., NguyenA.T., ZingraffJ., UrenaP., Descamps LatschaB.Influence of uremia and hemodialysis on circulating interleukin-l and tumor necrosis factoralpha.Kidney Int1990; 37: 116–25.
36.
GirndtM., KohlerH., Schiedhelm-WeickE., SchlaakJ.F., MezerK.H., FleischerB.Production of interleukin-6, tumor necrosis factor-a and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients.Kidney Int1995; 47: 559–65.
37.
BetzM., HaenschG.M., RauterbergE.W., BommerJ., RitzE.Cuprammonium membranes stimulate interleukin-l release and arachidonic acid metabolism in monocytes in the absence of complement.Kidney Int1988; 34: 67–71.
38.
LebelM., GroseJ.H., KingmaI., LangloisS.Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy.Clin Exp Hypertens1994; 16: 565–75.
39.
ShichiriM., HirataY., AndoK., EmoriT., OhtaK., KimotoS.Plasma endothelin levels in hypertension and chronic renal failure.Hypertension1990; 15: 493–6.
40.
FerriC., BelliniC., DesideriG., Di FranscescoL., BaldonciniR., SantucciA.Plasma endothelin-l levels in obese hypertensive and normotensive men.Diabetes1995; 44: 431–6.
41.
LightfootB.O., CaruanaR.J.Endothelin-l in continuous ambulatory peritoneal dialysis and hemodialysis patients. A preliminary study.Perit Dial Int1993; 13: 55–8.
